Reginaldo Prioli , Ph.D.

Reggie Prioli, Ph.D, Associate Director of Conjugation at Cell Signaling Technology® (CST®), has been conjugating antibodies at CST since 2008. Before CST, he directed the development of ELISA assays for HIV (Immunetics), erythropoietin (Genzyme -FDA approved assay) and aflatoxin (Vicam). Reggie has published over 20 peer reviewed papers. He received his BS in Biology in Brazil, his PhD from University of London and did his post-doc at TUFTS University- New England Medical Center. Reggie is passionate about bioconjugation, resides north of Boston and enjoys skiing.

Cell counts for each biomarker were divided by total number of cells to give a percentage of biomarker positive cells out of total cells for each biomarker.

Methods to Improve Reproducibility in Spatial Biology Research

Establish reproducibility results for a Cell DIVE multiplexed imaging study in cancer research using the BAB 200 automated system from ASLS and validated antibodies from CST

PDAC Multiplexed imaging of CST panels enables an examination of immune cell components in pancreatic ductal adenocarcinoma (IPDAC) tissue on a single slide.

Characterizing tumor environment to reveal insights and spatial resolution

Antibodies from Cell Signaling Technology are validated for use with the Cell DIVE multiplexing workflow and used to probe cell lineages in the tumor microenvironment